Literature DB >> 29703491

Thrombosis in pediatric patients with leukemia.

Sarina Levy-Mendelovich1, Assaf Arie Barg1, Gili Kenet2.   

Abstract

Acute lymphoblastic leukemia (ALL) is the most common type of cancer diagnosed in children. It is reportedly the most common malignancy associated with thromboembolism in the pediatric age group. Over the last 2 decades, venous thromboembolism (VTE) has been increasingly diagnosed among pediatric ALL patients with an estimated incidence ranging from about 5% (for symptomatic cases) to about 30-70% (following sequential imaging studies in asymptomatic children). The etiology is multifactorial and may stem from alterations of the hemostatic system following various chemotherapy protocols (including use of l-Asparaginase), the presence of central venous lines (CVL), as well as comorbidities, e.g. inherited thrombophilia risk factors. Most symptomatic thrombotic events occur in the upper venous system or in the central nervous system (CNS). Prospective studies on the establishment of guidelines for treatment or prevention are lacking. The following review will address the epidemiology, etiology and risk factors for thrombosis, describe the currently available evidence, and address issues associated with diagnosis and treatment.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ALL; Asparaginase; Pediatric CVL; Thrombophilia; Thrombosis

Mesh:

Year:  2018        PMID: 29703491     DOI: 10.1016/j.thromres.2018.01.019

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

1.  A pilot study of procoagulant platelet extracellular vesicles and P-selectin increase during induction treatment in acute lymphoblastic leukaemia paediatric patients: two new biomarkers of thrombogenic risk?

Authors:  Claire Pluchart; Coralie Barbe; Gael Poitevin; Sandra Audonnet; Philippe Nguyen
Journal:  J Thromb Thrombolysis       Date:  2020-11-28       Impact factor: 2.300

Review 2.  Thrombotic complications in patients with cancer: Advances in pathogenesis, prevention, and treatment-A report from ICTHIC 2021.

Authors:  Anna Falanga; Benjamin Brenner; Alok A Khorana; Charles W Francis
Journal:  Res Pract Thromb Haemost       Date:  2022-07-01

3.  Endothelial dysfunction and thromboembolism in children, adolescents, and young adults with acute lymphoblastic leukemia.

Authors:  Liv Andrés-Jensen; Kathrine Grell; Cecilie Utke Rank; Birgitte Klug Albertsen; Ruta Tuckuviene; Rikke Linnemann Nielsen; Line Stensig Lynggaard; Kirsten Brunsvig Jarvis; Petter Quist-Paulsen; Sonata Saulyte Trakymiene; Rūta Semaškevičienė; Kadri Saks; Olafur Gisli Jonsson; Thomas Leth Frandsen; Pär Ingemar Johansson; Kjeld Schmiegelow
Journal:  Leukemia       Date:  2021-08-13       Impact factor: 11.528

4.  Risk factors for the development of hospital-acquired pediatric venous thromboembolism-Dealing with potentially causal and confounding risk factors using a directed acyclic graph (DAG) analysis.

Authors:  Leonardo Rodrigues Campos; Maurício Petroli; Flavio Roberto Sztajnbok; Elaine Sobral da Costa; Leonardo Rodrigues Brandão; Marcelo Gerardin Poirot Land
Journal:  PLoS One       Date:  2020-11-13       Impact factor: 3.240

5.  Dynamic Changes in the Ability to Release Neutrophil ExtraCellular Traps in the Course of Childhood Acute Leukemias.

Authors:  Magdalena Ostafin; Olga Ciepiela; Michał Pruchniak; Małgorzata Wachowska; Edyta Ulińska; Piotr Mrówka; Eliza Głodkowska-Mrówka; Urszula Demkow
Journal:  Int J Mol Sci       Date:  2021-01-15       Impact factor: 5.923

6.  Thrombosis and Anticoagulant Therapy Among Pediatric Cancer Patients: Real-Life Data.

Authors:  Hasan Hashem; Momen Zeineddin; Rayan Bater; Nisreen Amayiri; Wiam Al Qasem; Bilasan Hammo; Iyad Sultan; Rama AlMasri; Hikmat Abdel-Razeq
Journal:  Cureus       Date:  2021-12-01

7.  Stroke in Middle Eastern children with cancer: prevalence and risk factors.

Authors:  Catherina Zadeh; Natally AlArab; Samar Muwakkit; Lamya A Atweh; Hani Tamim; Maha Makki; Hamza A Salhab; Roula Hourani
Journal:  BMC Neurol       Date:  2022-01-18       Impact factor: 2.474

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.